A 52-year-old man with type 2 diabetes (HbA1c 9.2%) and chronic kidney disease (eGFR 35 mL/min) presents with fever (39.1°C), dysuria, and flank pain for 3 days. He also reports nausea and vomiting. On examination, he is tachycardic (HR 102/min), blood pressure 108/70 mmHg, and has costovertebral angle tenderness bilaterally. Urinalysis shows pyuria, bacteriuria, and white cell casts. Blood culture and urine culture are sent. Serum creatinine is 2.8 mg/dL (baseline 1.9 mg/dL). Which organism is most likely, and what is the key virulence factor that predisposes this patient to upper UTI?

Explanation

## Clinical Diagnosis This patient presents with acute pyelonephritis (fever, flank pain, bilateral CVA tenderness, pyuria with white cell casts) in the setting of type 2 diabetes and chronic kidney disease—both risk factors for complicated UTI and upper tract involvement. The tachycardia and borderline hypotension suggest early sepsis with acute-on-chronic kidney injury. ## Organism Identification and Epidemiology **High-Yield:** **Escherichia coli** is the most common cause of both uncomplicated AND complicated UTI, including pyelonephritis in diabetic and CKD patients. It accounts for approximately 70–80% of community-acquired UTIs and remains the predominant uropathogen even in high-risk hosts such as: - Patients with diabetes mellitus - Patients with chronic kidney disease - Elderly patients - Immunocompromised individuals While Proteus mirabilis, Klebsiella pneumoniae, and Enterococcus faecalis are more prevalent in complicated UTI relative to uncomplicated UTI, E. coli still dominates across all UTI categories in community settings (Harrison's Principles of Internal Medicine, 21e, Ch. 130; Jawetz Medical Microbiology, 28e, Ch. 16). ## Key Virulence Factor: O Antigen Variation and Immune Evasion **Key Point:** The **O antigen** (somatic lipopolysaccharide antigen) of E. coli is a critical virulence determinant for upper UTI. Its role includes: 1. **Complement evasion**: Variation in O antigen structure interferes with complement activation and deposition of C3b, reducing opsonization and bactericidal killing. 2. **Phagocytosis resistance**: O antigen variation reduces recognition by phagocytic pattern-recognition receptors, allowing bacterial survival in renal tissue. 3. **Serum resistance**: Uropathogenic E. coli (UPEC) strains with specific O serotypes (e.g., O1, O2, O4, O6, O75) are strongly associated with pyelonephritis and bacteremia due to enhanced serum resistance. 4. **Additional UPEC virulence factors** (supporting context): P fimbriae (bind uroepithelium), α-hemolysin (cytotoxin), and aerobactin (iron acquisition) further facilitate upper tract invasion. **Mnemonic:** **UPEC POPS** — **U**ropathogenic E. coli uses **P**-fimbriae, **O**-antigen variation, **P**-hemolysin, and **S**iderophores to cause pyelonephritis. ## Why the Other Options Are Incorrect | Option | Organism | Issue | |--------|----------|-------| | **A** | Klebsiella pneumoniae; ESBL | ESBL is a resistance mechanism, NOT a virulence factor predisposing to upper UTI. K. pneumoniae is less common than E. coli even in complicated UTI. | | **C** | Enterococcus faecalis | Enterococcus is NOT intrinsically resistant to vancomycin (only VRE strains are). It is also a less common uropathogen in community-acquired pyelonephritis. | | **D** | Proteus mirabilis; urease | P. mirabilis is classically associated with obstructive/stone-related UTI and catheter-associated UTI. Urease is a genuine virulence factor, but P. mirabilis is far less common than E. coli even in CKD/diabetes without structural abnormality or stones. | ## Pathophysiology in This Patient ``` E. coli (UPEC) → Colonizes periurethral area → Ascends to bladder → P fimbriae bind uroepithelium → Ascends to upper tract → O antigen variation evades complement + phagocytosis → Renal parenchymal invasion → Pyelonephritis + bacteremia → Sepsis + AKI in CKD/diabetic host ``` ## Management Implications **High-Yield:** Empiric management of complicated pyelonephritis (E. coli most likely): 1. **IV antibiotics**: Ceftriaxone 1–2 g IV OD or piperacillin-tazobactam (if ESBL risk); adjust for eGFR 35. 2. **Blood and urine cultures**: Guide de-escalation to oral fluoroquinolone or trimethoprim-sulfamethoxazole based on sensitivities. 3. **Imaging**: Renal ultrasound or CT to exclude obstruction, abscess, or emphysematous pyelonephritis (higher risk in diabetes). 4. **Glycemic control**: Hyperglycemia (HbA1c 9.2%) impairs neutrophil function and promotes bacterial growth. [cite: Harrison's Principles of Internal Medicine 21e Ch. 130; Jawetz, Melnick & Adelberg's Medical Microbiology 28e Ch. 16; Mandell, Douglas & Bennett's Principles of Infectious Diseases 9e Ch. 58]